Creative Diagnostics Launches Its IHC Antibodies for Pathology
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics announces the introduction of a variety of IHC antibodies for pathology research usage. A number of high quality pathology recombinant monoclonal antibodies including Her2, PD-1, Ki-67, Tim3, CTLA4, Lp-PLA2, Muc2, Cytokeratin 18, BRAF V600E, IDH1 R132H, MLH1, MSH2, MSH6, and PMS2 are developed by Creative Diagnostics and are available now.
These new antibodies have been extensively tested and validated for immunohistochemistry on human tissues and are engineered to deliver consistent, specific, and sensitive stains. Creative Diagnostics' IHC antibodies have been characterized at different concentrations against normal human or diseased tissues and additional relevant controls, and are presented as prediluted format as well as concentrated format. FSH monoclonal antibody(CABT-L2883), the pathology antibody for immunohistochemistry use for instance, is hormone synthesized and secreted by gonadotropes in the anterior pituitary gland and is a useful marker in the classification of pituitary tumors and the study of pituitary disease.
Immunohistochemistry in molecular pathology plays important diagnostic, prognostic and predictive roles, and IHC antibodies have been identified as the best reagents for use in immunohistochemistry on formalin-fixed paraffin sections. Diagnostics implement quality control for immunohistochemistry staining methods and interpretation in pathology laboratories.
"Creative Diagnostics is proud to provide scientists with these new IHC antibodies for a variety of research and pharmaceutical applications. Together with our other antibodies, we'll continue to provide excellent performance and clinically relevant antibodies and cost-effective solutions to the pathology market." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
"Creative Diagnostics is committed to providing a range of innovative solutions and technologies to research community, and the addition of IHC antibodies to our broad portfolio further enables our support of scientific studies. All of our IHC antibodies are for research use only, and can be optimized to meet the needs of laboratories when combined with our cost effective solutions." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more information about IHC antibodies for pathology or other antibodies, please contact Creative Diagnostics.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.